Does the media favor TECX or ADCT?

In the previous week, Tectonic Therapeutic and Tectonic Therapeutic both had 3 articles in the media. Tectonic Therapeutic's average media sentiment score of 1.03 beat ADC Therapeutics' score of 0.56 indicating that Tectonic Therapeutic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tectonic Therapeutic 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ADC Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ADCT or CAPR?

In the previous week, Capricor Therapeutics had 38 more articles in the media than ADC Therapeutics. MarketBeat recorded 41 mentions for Capricor Therapeutics and 3 mentions for ADC Therapeutics. ADC Therapeutics' average media sentiment score of 0.56 beat Capricor Therapeutics' score of 0.09 indicating that ADC Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADC Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Capricor Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 38 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ADCT or ALT?

In the previous week, ADC Therapeutics and ADC Therapeutics both had 3 articles in the media. Altimmune's average media sentiment score of 1.17 beat ADC Therapeutics' score of 0.56 indicating that Altimmune is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADC Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Altimmune 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, ARVN or ADCT?

Arvinas has higher revenue and earnings than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Arvinas $262.60M 2.08 -$80.80M $0.10 84.50 ADC Therapeutics $81.36M 1.67 -$142.62M -$0.66 N/A

Is ARVN or ADCT more profitable?

Arvinas has a net margin of 2.94% compared to ADC Therapeutics' net margin of -121.77%. Arvinas' return on equity of 1.91% beat ADC Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Arvinas 2.94% 1.91% 1.29% ADC Therapeutics -121.77% N/A -32.74%

Does the media prefer ARVN or ADCT?

In the previous week, Arvinas had 3 more articles in the media than ADC Therapeutics. MarketBeat recorded 6 mentions for Arvinas and 3 mentions for ADC Therapeutics. ADC Therapeutics' average media sentiment score of 0.56 beat Arvinas' score of 0.03 indicating that ADC Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arvinas 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral ADC Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ADCT or EIKN more profitable?

Eikon Therapeutics has a net margin of 0.00% compared to ADC Therapeutics' net margin of -121.77%. Company Net Margins Return on Equity Return on Assets ADC Therapeutics -121.77% N/A -32.74% Eikon Therapeutics N/A N/A N/A

Does the media refer more to ADCT or EIKN?

In the previous week, Eikon Therapeutics had 6 more articles in the media than ADC Therapeutics. MarketBeat recorded 9 mentions for Eikon Therapeutics and 3 mentions for ADC Therapeutics. Eikon Therapeutics' average media sentiment score of 1.05 beat ADC Therapeutics' score of 0.56 indicating that Eikon Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADC Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eikon Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ADC Therapeutics (ADCT) Competitors

$1.06 -0.05 (-4.05%)

Closing price 09/11/2026 03:58 PM Eastern

Extended Trading

$1.06 0.00 (0.00%)

As of 09/11/2026 07:30 PM Eastern

Compare

ADCT vs. TECX, CAPR, ALT, ARVN, and EIKN

Should you buy ADC Therapeutics stock or one of its competitors? ADC Therapeutics's main competitors and comparable companies include Tectonic Therapeutic (TECX), Capricor Therapeutics (CAPR), Altimmune (ALT), Arvinas (ARVN), and Eikon Therapeutics (EIKN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ADC Therapeutics compare to Tectonic Therapeutic?

Tectonic Therapeutic (NASDAQ:TECX) and ADC Therapeutics (NYSE:ADCT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

Tectonic Therapeutic presently has a consensus target price of $77.25, suggesting a potential upside of 165.92%. ADC Therapeutics has a consensus target price of $5.00, suggesting a potential upside of 369.48%. Given ADC Therapeutics' higher possible upside, analysts clearly believe ADC Therapeutics is more favorable than Tectonic Therapeutic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tectonic Therapeutic	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Tectonic Therapeutic has a beta of 3.31, meaning that its stock price is 231% more volatile than the broader market. Comparatively, ADC Therapeutics has a beta of 1.84, meaning that its stock price is 84% more volatile than the broader market.

In the previous week, Tectonic Therapeutic and Tectonic Therapeutic both had 3 articles in the media. Tectonic Therapeutic's average media sentiment score of 1.03 beat ADC Therapeutics' score of 0.56 indicating that Tectonic Therapeutic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tectonic Therapeutic	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADC Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tectonic Therapeutic has higher earnings, but lower revenue than ADC Therapeutics. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.57	N/A
ADC Therapeutics	$81.36M	1.67	-$142.62M	-$0.66	N/A

Tectonic Therapeutic has a net margin of 0.00% compared to ADC Therapeutics' net margin of -121.77%. ADC Therapeutics' return on equity of 0.00% beat Tectonic Therapeutic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tectonic Therapeutic	N/A	-35.26%	-33.59%
ADC Therapeutics	-121.77%	N/A	-32.74%

62.6% of Tectonic Therapeutic shares are held by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are held by institutional investors. 39.8% of Tectonic Therapeutic shares are held by company insiders. Comparatively, 5.1% of ADC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Tectonic Therapeutic beats ADC Therapeutics on 9 of the 15 factors compared between the two stocks.

How does ADC Therapeutics compare to Capricor Therapeutics?

ADC Therapeutics (NYSE:ADCT) and Capricor Therapeutics (NASDAQ:CAPR) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

ADC Therapeutics presently has a consensus target price of $5.00, suggesting a potential upside of 369.48%. Capricor Therapeutics has a consensus target price of $29.15, suggesting a potential upside of 248.27%. Given ADC Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe ADC Therapeutics is more favorable than Capricor Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Capricor Therapeutics	1 Sell rating(s)	7 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18

Capricor Therapeutics has a net margin of 0.00% compared to ADC Therapeutics' net margin of -121.77%. ADC Therapeutics' return on equity of 0.00% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADC Therapeutics	-121.77%	N/A	-32.74%
Capricor Therapeutics	N/A	-56.60%	-43.97%

Capricor Therapeutics has lower revenue, but higher earnings than ADC Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADC Therapeutics	$81.36M	1.67	-$142.62M	-$0.66	N/A
Capricor Therapeutics	$22.27M	21.85	-$105.04M	-$2.45	N/A

41.1% of ADC Therapeutics shares are held by institutional investors. Comparatively, 21.7% of Capricor Therapeutics shares are held by institutional investors. 5.1% of ADC Therapeutics shares are held by insiders. Comparatively, 9.2% of Capricor Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

ADC Therapeutics has a beta of 1.84, suggesting that its stock price is 84% more volatile than the broader market. Comparatively, Capricor Therapeutics has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market.

In the previous week, Capricor Therapeutics had 38 more articles in the media than ADC Therapeutics. MarketBeat recorded 41 mentions for Capricor Therapeutics and 3 mentions for ADC Therapeutics. ADC Therapeutics' average media sentiment score of 0.56 beat Capricor Therapeutics' score of 0.09 indicating that ADC Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADC Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Capricor Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	38 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ADC Therapeutics beats Capricor Therapeutics on 10 of the 15 factors compared between the two stocks.

How does ADC Therapeutics compare to Altimmune?

ADC Therapeutics (NYSE:ADCT) and Altimmune (NASDAQ:ALT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

41.1% of ADC Therapeutics shares are held by institutional investors. Comparatively, 78.1% of Altimmune shares are held by institutional investors. 5.1% of ADC Therapeutics shares are held by company insiders. Comparatively, 1.6% of Altimmune shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

ADC Therapeutics has a net margin of -121.77% compared to Altimmune's net margin of -214,860.98%. ADC Therapeutics' return on equity of 0.00% beat Altimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADC Therapeutics	-121.77%	N/A	-32.74%
Altimmune	-214,860.98%	-31.41%	-26.96%

ADC Therapeutics has a beta of 1.84, meaning that its stock price is 84% more volatile than the broader market. Comparatively, Altimmune has a beta of 0.18, meaning that its stock price is 82% less volatile than the broader market.

ADC Therapeutics currently has a consensus price target of $5.00, indicating a potential upside of 369.48%. Altimmune has a consensus price target of $14.33, indicating a potential upside of 338.33%. Given ADC Therapeutics' higher possible upside, equities analysts plainly believe ADC Therapeutics is more favorable than Altimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Altimmune	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Altimmune has lower revenue, but higher earnings than ADC Therapeutics. Altimmune is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADC Therapeutics	$81.36M	1.67	-$142.62M	-$0.66	N/A
Altimmune	$40K	15,902.01	-$88.09M	-$0.78	N/A

In the previous week, ADC Therapeutics and ADC Therapeutics both had 3 articles in the media. Altimmune's average media sentiment score of 1.17 beat ADC Therapeutics' score of 0.56 indicating that Altimmune is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADC Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Altimmune	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ADC Therapeutics beats Altimmune on 8 of the 15 factors compared between the two stocks.

How does ADC Therapeutics compare to Arvinas?

Arvinas (NASDAQ:ARVN) and ADC Therapeutics (NYSE:ADCT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

Arvinas has a beta of 1.75, meaning that its stock price is 75% more volatile than the broader market. Comparatively, ADC Therapeutics has a beta of 1.84, meaning that its stock price is 84% more volatile than the broader market.

Arvinas has a net margin of 2.94% compared to ADC Therapeutics' net margin of -121.77%. Arvinas' return on equity of 1.91% beat ADC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arvinas	2.94%	1.91%	1.29%
ADC Therapeutics	-121.77%	N/A	-32.74%

Arvinas has higher revenue and earnings than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arvinas	$262.60M	2.08	-$80.80M	$0.10	84.50
ADC Therapeutics	$81.36M	1.67	-$142.62M	-$0.66	N/A

Arvinas presently has a consensus price target of $14.17, indicating a potential upside of 67.65%. ADC Therapeutics has a consensus price target of $5.00, indicating a potential upside of 369.48%. Given ADC Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe ADC Therapeutics is more favorable than Arvinas.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arvinas	2 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.27
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

95.2% of Arvinas shares are held by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are held by institutional investors. 7.3% of Arvinas shares are held by insiders. Comparatively, 5.1% of ADC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Arvinas had 3 more articles in the media than ADC Therapeutics. MarketBeat recorded 6 mentions for Arvinas and 3 mentions for ADC Therapeutics. ADC Therapeutics' average media sentiment score of 0.56 beat Arvinas' score of 0.03 indicating that ADC Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arvinas	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
ADC Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Arvinas beats ADC Therapeutics on 12 of the 16 factors compared between the two stocks.

How does ADC Therapeutics compare to Eikon Therapeutics?

ADC Therapeutics (NYSE:ADCT) and Eikon Therapeutics (NASDAQ:EIKN) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

ADC Therapeutics currently has a consensus price target of $5.00, suggesting a potential upside of 369.48%. Eikon Therapeutics has a consensus price target of $25.00, suggesting a potential upside of 179.64%. Given ADC Therapeutics' higher probable upside, equities research analysts plainly believe ADC Therapeutics is more favorable than Eikon Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Eikon Therapeutics had 6 more articles in the media than ADC Therapeutics. MarketBeat recorded 9 mentions for Eikon Therapeutics and 3 mentions for ADC Therapeutics. Eikon Therapeutics' average media sentiment score of 1.05 beat ADC Therapeutics' score of 0.56 indicating that Eikon Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADC Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eikon Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

41.1% of ADC Therapeutics shares are held by institutional investors. 5.1% of ADC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Eikon Therapeutics has a net margin of 0.00% compared to ADC Therapeutics' net margin of -121.77%.

Company	Net Margins	Return on Equity	Return on Assets
ADC Therapeutics	-121.77%	N/A	-32.74%
Eikon Therapeutics	N/A	N/A	N/A

ADC Therapeutics has higher revenue and earnings than Eikon Therapeutics. Eikon Therapeutics is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADC Therapeutics	$81.36M	1.67	-$142.62M	-$0.66	N/A
Eikon Therapeutics	N/A	N/A	-$324.25M	-$4.09	N/A

Summary

ADC Therapeutics and Eikon Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get ADC Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADCT vs. The Competition

Export

Metric	ADC Therapeutics	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$136.60M	$3.85B	$7.16B	$23.38B
Dividend Yield	N/A	3.65%	2.57%	3.56%
P/E Ratio	-1.61	14.18	274.94	28.72
Price / Sales	1.67	1,374.96	685.44	21.18
Price / Cash	N/A	106.50	76.65	34.17
Price / Book	-0.71	15.12	10.33	4.74
Net Income	-$142.62M	-$22.86M	$3.50B	$1.07B
7 Day Performance	-21.69%	-4.34%	-3.32%	-2.00%
1 Month Performance	1.91%	0.54%	-0.53%	-3.20%
1 Year Performance	-67.82%	40.74%	23.51%	10.51%

ADC Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADCT ADC Therapeutics	2.3656 of 5 stars	$1.07 -4.1%	$5.00 +369.5%	-67.8%	$136.60M	$81.36M	N/A	310
TECX Tectonic Therapeutic	2.819 of 5 stars	$31.03 +3.6%	$77.80 +150.7%	+63.9%	$610.35M	N/A	N/A	120	News Coverage
CAPR Capricor Therapeutics	2.9358 of 5 stars	$10.25 +3.4%	$29.15 +184.4%	+31.6%	$598.49M	$22.27M	N/A	101	Trending News
ALT Altimmune	2.5274 of 5 stars	$3.07 -1.4%	$14.33 +367.6%	-10.2%	$598.15M	$40K	N/A	50
ARVN Arvinas	2.7744 of 5 stars	$9.17 -0.3%	$14.17 +54.5%	+9.2%	$593.20M	$262.60M	91.95	420	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ADCT) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ADC Therapeutics (ADCT) Competitors

ADCT vs. TECX, CAPR, ALT, ARVN, and EIKN

How does ADC Therapeutics compare to Tectonic Therapeutic?

Summary

How does ADC Therapeutics compare to Capricor Therapeutics?

Summary

How does ADC Therapeutics compare to Altimmune?

Summary

How does ADC Therapeutics compare to Arvinas?

Summary

How does ADC Therapeutics compare to Eikon Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADCT vs. The Competition

ADC Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ADC Therapeutics (ADCT) Competitors

ADCT vs. TECX, CAPR, ALT, ARVN, and EIKN

How does ADC Therapeutics compare to Tectonic Therapeutic?

Do analysts rate TECX or ADCT?

Which has more volatility and risk, TECX or ADCT?

Does the media favor TECX or ADCT?

Which has better valuation & earnings, TECX or ADCT?

Is TECX or ADCT more profitable?

Do institutionals & insiders believe in TECX or ADCT?

Summary

How does ADC Therapeutics compare to Capricor Therapeutics?

Do analysts prefer ADCT or CAPR?

Is ADCT or CAPR more profitable?

Which has preferable valuation & earnings, ADCT or CAPR?

Do institutionals and insiders believe in ADCT or CAPR?

Which has more volatility & risk, ADCT or CAPR?

Does the media refer more to ADCT or CAPR?

Summary

How does ADC Therapeutics compare to Altimmune?

Do institutionals and insiders have more ownership in ADCT or ALT?

Is ADCT or ALT more profitable?

Which has more volatility and risk, ADCT or ALT?

Do analysts recommend ADCT or ALT?

Which has better earnings & valuation, ADCT or ALT?

Does the media refer more to ADCT or ALT?

Summary

How does ADC Therapeutics compare to Arvinas?

Which has more risk & volatility, ARVN or ADCT?

Is ARVN or ADCT more profitable?

Which has better valuation and earnings, ARVN or ADCT?

Do analysts rate ARVN or ADCT?

Do institutionals and insiders believe in ARVN or ADCT?

Does the media prefer ARVN or ADCT?

Summary

How does ADC Therapeutics compare to Eikon Therapeutics?

Do analysts prefer ADCT or EIKN?

Does the media refer more to ADCT or EIKN?

Do institutionals & insiders hold more shares of ADCT or EIKN?

Is ADCT or EIKN more profitable?

Which has preferable valuation & earnings, ADCT or EIKN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADCT vs. The Competition

ADC Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools